These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 17383431)

  • 21. Effect of a Vasopressin V2 Receptor Antagonist on Polycystic Kidney Disease Development in a Rat Model.
    Wang X; Constans MM; Chebib FT; Torres VE; Pellegrini L
    Am J Nephrol; 2019; 49(6):487-493. PubMed ID: 31117065
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models.
    Lee-Law PY; Olaizola P; Caballero-Camino FJ; Izquierdo-Sanchez L; Rodrigues PM; Santos-Laso A; Azkargorta M; Elortza F; Martinez-Chantar ML; Perugorria MJ; Aspichueta P; Marzioni M; LaRusso NF; Bujanda L; Drenth JPH; Banales JM
    J Hepatol; 2021 Feb; 74(2):394-406. PubMed ID: 32950589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renin-angiotensin system activation in congenital hepatic fibrosis in the PCK rat model of autosomal recessive polycystic kidney disease.
    Goto M; Hoxha N; Osman R; Wen J; Wells RG; Dell KM
    J Pediatr Gastroenterol Nutr; 2010 Jun; 50(6):639-44. PubMed ID: 20400910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epidermal growth factor receptor tyrosine kinase inhibition is not protective in PCK rats.
    Torres VE; Sweeney WE; Wang X; Qian Q; Harris PC; Frost P; Avner ED
    Kidney Int; 2004 Nov; 66(5):1766-73. PubMed ID: 15496147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tissue culture correlational study of genetic cholangiopathy of autosomal recessive polycystic kidney disease.
    Nakanuma Y; Sato Y; Harada K
    Methods Mol Biol; 2013; 945():303-18. PubMed ID: 23097114
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disease stage characterization of hepatorenal fibrocystic pathology in the PCK rat model of ARPKD.
    Mason SB; Liang Y; Sinders RM; Miller CA; Eggleston-Gulyas T; Crisler-Roberts R; Harris PC; Gattone VH
    Anat Rec (Hoboken); 2010 Aug; 293(8):1279-88. PubMed ID: 20665806
    [TBL] [Abstract][Full Text] [Related]  

  • 27. B-type natriuretic peptide overexpression ameliorates hepatorenal fibrocystic disease in a rat model of polycystic kidney disease.
    Holditch SJ; Schreiber CA; Harris PC; LaRusso NF; Ramirez-Alvarado M; Cataliotti A; Torres VE; Ikeda Y
    Kidney Int; 2017 Sep; 92(3):657-668. PubMed ID: 28416225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic blockade of 20-HETE synthesis reduces polycystic kidney disease in an orthologous rat model of ARPKD.
    Park F; Sweeney WE; Jia G; Akbulut T; Mueller B; Falck JR; Birudaraju S; Roman RJ; Avner ED
    Am J Physiol Renal Physiol; 2009 Mar; 296(3):F575-82. PubMed ID: 19129252
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blockade of Hedgehog Signaling Attenuates Biliary Cystogenesis in the Polycystic Kidney (PCK) Rat.
    Sato Y; Yamamura M; Sasaki M; Harada K
    Am J Pathol; 2018 Oct; 188(10):2251-2263. PubMed ID: 30036521
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biliary dysgenesis in the PCK rat, an orthologous model of autosomal recessive polycystic kidney disease.
    Masyuk TV; Huang BQ; Masyuk AI; Ritman EL; Torres VE; Wang X; Harris PC; Larusso NF
    Am J Pathol; 2004 Nov; 165(5):1719-30. PubMed ID: 15509540
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proliferation-Independent Initiation of Biliary Cysts in Polycystic Liver Diseases.
    Beaudry JB; Cordi S; Demarez C; Lepreux S; Pierreux CE; Lemaigre FP
    PLoS One; 2015; 10(6):e0132295. PubMed ID: 26125584
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HDAC6 is overexpressed in cystic cholangiocytes and its inhibition reduces cystogenesis.
    Gradilone SA; Habringer S; Masyuk TV; Howard BN; Masyuk AI; Larusso NF
    Am J Pathol; 2014 Mar; 184(3):600-8. PubMed ID: 24434010
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantitative magnetic resonance imaging assessments of autosomal recessive polycystic kidney disease progression and response to therapy in an animal model.
    Erokwu BO; Anderson CE; Flask CA; Dell KM
    Pediatr Res; 2018 May; 83(5):1067-1074. PubMed ID: 29538364
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bile Acids in Polycystic Liver Diseases: Triggers of Disease Progression and Potential Solution for Treatment.
    Perugorria MJ; Labiano I; Esparza-Baquer A; Marzioni M; Marin JJ; Bujanda L; Banales JM
    Dig Dis; 2017; 35(3):275-281. PubMed ID: 28249268
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adenylyl cyclase 5 links changes in calcium homeostasis to cAMP-dependent cyst growth in polycystic liver disease.
    Spirli C; Mariotti V; Villani A; Fabris L; Fiorotto R; Strazzabosco M
    J Hepatol; 2017 Mar; 66(3):571-580. PubMed ID: 27826057
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improved Structure and Function in Autosomal Recessive Polycystic Rat Kidneys with Renal Tubular Cell Therapy.
    Kelly KJ; Zhang J; Han L; Kamocka M; Miller C; Gattone VH; Dominguez JH
    PLoS One; 2015; 10(7):e0131677. PubMed ID: 26136112
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The pck rat: a new model that resembles human autosomal dominant polycystic kidney and liver disease.
    Lager DJ; Qian Q; Bengal RJ; Ishibashi M; Torres VE
    Kidney Int; 2001 Jan; 59(1):126-36. PubMed ID: 11135065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease.
    Yoshihara D; Kurahashi H; Morita M; Kugita M; Hiki Y; Aukema HM; Yamaguchi T; Calvet JP; Wallace DP; Nagao S
    Am J Physiol Renal Physiol; 2011 Feb; 300(2):F465-74. PubMed ID: 21147840
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Initial evaluation of hepatic T1 relaxation time as an imaging marker of liver disease associated with autosomal recessive polycystic kidney disease (ARPKD).
    Gao Y; Erokwu BO; DeSantis DA; Croniger CM; Schur RM; Lu L; Mariappuram J; Dell KM; Flask CA
    NMR Biomed; 2016 Jan; 29(1):84-9. PubMed ID: 26608869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TGR5 in the Cholangiociliopathies.
    Masyuk TV; Masyuk AI; LaRusso NF
    Dig Dis; 2015; 33(3):420-5. PubMed ID: 26045278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.